Investor FAQs
Company Overview
What does Azora Therapeutics do?
Azora Therapeutics is a clinical-stage biopharmaceutical company developing differentiated therapies for serious immune-mediated and inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor (AhR) agonist in development for ulcerative colitis.
When was Azora Therapeutics founded?
Azora Therapeutics originated from Stanford University’s SPARK translational medicine program. An exact founding date is not currently published on this site; please contact Investor Relations for additional corporate-history information.
Where is Azora Therapeutics headquartered?
Azora Therapeutics lists its principal company contact at:
16501 Ventura Blvd, Suite 400
Encino, CA 91436
Who leads Azora Therapeutics?
Azora Therapeutics is led by co-founder and Chief Executive Officer Matt Davidson, Ph.D., together with its executive leadership team. The current team is listed on the Leadership section.
What industry does Azora Therapeutics operate in?
Azora Therapeutics operates in the biopharmaceutical industry, with a focus on clinical-stage drug development for inflammatory and immune-mediated diseases.
Business and Pipeline
What products or services does Azora Therapeutics offer?
Azora Therapeutics is developing investigational product candidates rather than currently marketed products. Its pipeline includes AT177 for ulcerative colitis and Adial's asset AD04 for Alcohol Use Disorder. These candidates have not been approved by the FDA or any other regulatory authority.
How does Azora Therapeutics generate revenue?
Azora Therapeutics does not currently generate product revenue from approved medicines. Its development activities are financed through capital raising and may also be supported by future collaborations, licensing arrangements or strategic partnerships.
What is Azora Therapeutics’ business model?
The company advances differentiated drug candidates through preclinical and clinical development, seeking to create value through regulatory progress, potential approvals, commercialization and selected development or licensing partnerships.
What markets or regions does Azora Therapeutics serve?
Azora Therapeutics is not currently commercializing an approved product in any market. Its programs are being developed for diseases affecting patients globally, with future availability dependent on clinical results and regulatory approvals in each region.
Who are Azora Therapeutics’ customers?
Because Azora Therapeutics does not currently market an approved product, it does not yet have commercial product customers. If a candidate is approved, its stakeholders could include patients, healthcare professionals, health systems and payers.
What differentiates Azora Therapeutics from its competitors?
Azora’s lead program combines clinically validated AhR biology with a colon-targeted design intended to act locally while minimizing systemic exposure. AT177 is designed to deliver a potent AhR agonist directly at the site of disease.
What is Azora Therapeutics’ growth strategy?
The company’s near-term strategy is to advance AT177 through IND-enabling work and into clinical development, evaluate expansion into Crohn’s disease, progress AD04 toward a new Phase 3 program and build additional opportunities from its development platform.
Stockholder Information
Is Azora Therapeutics publicly traded?
Yes. Azora Therapeutics is a publicly traded company.
On which exchange is Azora Therapeutics listed?
Azora Therapeutics is listed on the Nasdaq Stock Market.
What is Azora Therapeutics’ stock ticker symbol?
The company’s stock ticker symbol is AZR.
Where can I find Azora Therapeutics’ financial reports and SEC filings?
Financial reports and regulatory filings are available on the SEC Filings page.
How can I listen to Azora Therapeutics’ earnings calls or investor presentations?
Conference calls and webcasts are posted on the Events page. Presentation materials are available on the Investor Presentations page, with the latest deck also featured on the IR Overview page.
Does Azora Therapeutics pay a dividend?
Azora Therapeutics does not currently pay a cash dividend and expects to retain available funds to support development and growth. Any future dividend would be subject to the Board of Directors’ discretion.
How can I contact Azora Therapeutics’ investor relations team?
Investor Relations contact details, including the dedicated phone number and email address, are available on the Contact page.
Where can I sign up for updates or news from Azora Therapeutics?
Visit the Email Alerts page to subscribe to company updates and investor news.